WS #13450

10:56→11:22 UTC

From 500 msgs · 7 key-dev

Eli Lilly Q2 revenue +48% to $23B, EPS $8.38 vs $8.38 est, raised FY26 guidance on strong Mounjaro/Zepbound demand, but M&A spending trims EPS outlook.

Eli Lilly GLP-1 earnings beat

Eli Lilly Q2 revenue +48% to $23B, EPS $8.38 vs $8.38 est, raised FY26 guidance on strong Mounjaro/Zepbound demand, but M&A spending trims EPS outlook.

Full world state #13450 →